| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 121 | Method for producing milk products having high concentrations of omega-3 highly unsaturated fatty acids | US09434695 | 1999-11-05 | US06177108B1 | 2001-01-23 | William R. Barclay |
| A process for the heterotrophic or predominantly heterotrophic production of whole-celled or extracted microbial products with a high concentration of omega-3 highly unsaturated fatty acids, producible in an aerobic culture under controlled conditions using biologically pure cultures of heterotrophic single-celled fungi microorganisms of the order Thraustochytriales. The harvested whole-cell microbial product can be added to processed foods as a nutritional supplement, or to fish and animal feeds to enhance the omega-3 highly unsaturated fatty acid content of products produced from these animals. The lipids containing these fatty acids can also be extracted and used in nutritional, pharmaceutical and industrial applications. | ||||||
| 122 | Production of recombinant polypeptides by bovine species and transgenic methods | US476798 | 1995-06-07 | US6140552A | 2000-10-31 | Herman A. Deboer; Rein Strijker; Herbert L. Heyneker; Gerard Platenburg; Sang He Lee; Frank Pieper; Paul J. A. Krimpenfort |
| Transgenes for producing recombinant polypeptides transgenic bovine species. A transgene for producing recombinant polypeptides in the milk of transgenic bovine species comprises at least one expression regulation sequence, a secretory DNA sequence encoding a secretory signal sequence which is functional in mammary secretory cells of the bovine species and a recombinant DNA sequence encoding the recombinant polypeptide. Also included are methods for producing transgenic bovine species. The method includes introducing the above transgene into an embryonal target cell of a bovine species, transplanting the transgenic embryonic target cell formed thereby into a recipient bovine parent and identifying at least one female offspring which is capable of producing the recombinant polypeptide in its milk. The invention also includes transgenic bovine species capable of producing recombinant polypeptides in transgenic milk as well as the milk from such transgenic bovine species and food formulations containing one or more recombinant polypeptide. Methods are also provided for producing transgenic non-human mammals having a desirable phenotype. The method comprises first methylating a transgene followed by introduction into fertilized oocytes. The oocytes are then cultured to form pre-implantation embryos. Thereafter, at least one cell is removed from each of the pre-implantation embryos and the DNA digested with a restriction endonuclease capable of cleaving the methylated transgene but incapable of cleaving the unmethylated form of the transgene. Those pre-implantation embryos which have integrated the transgene contain DNA which is resistant to cleavage by the restriction endonuclease in the region containing the transgene. | ||||||
| 123 | Immune suppressive product | US815630 | 1991-12-30 | US6054124A | 2000-04-25 | Lee R. Beck; Ralph J. Stolle |
| An immune suppressive product prepared by injecting an allergen or a mixture of allergens into the body of milk-producing species. Said product being the milk or a polypeptide subfraction of milk obtained from the allergen treated host. The immune suppressive product(s) is milk and or the polypeptide fractions contained therein, which is ostensively free of the intact allergen or allergens used for the treatment of the host. The immune suppressive factor(s) being a subfraction of the allergen used for the treatment. A method of preparing immune suppressive polypeptides from intact allergens, which involves injection of the specific intact allergens into a milk-producing species, collecting the immune suppressive polypeptide fractions of the intact allergens from the milk of the treated host. The immune suppressive milk containing said polypeptide fractions, and/or the polypeptide fractions obtained from said milk, are nonreactive in animals and humans as allergens. Said factor(s), however, are highly effective in preventing or alleviating allergic reactions. | ||||||
| 124 | Targeted synthesis of protein in mammary gland of a non-human transgenic mammal | US186836 | 1994-01-25 | US5994616A | 1999-11-30 | Jeffrey M. Rosen |
| Described are methods of targeting specific genes or DNA sequences encoding biologically active proteins to the mammary gland such that the DNA sequence is expressed in the mammary gland and the protein is secreted into the milk of the mammal. Also described is the production of transgenic nonhuman mammals whose germ line comprises a DNA gene complex containing a casein promoter, a casein enhancer, a DNA sequence which encodes a signal peptide and a DNA sequence encoding a biologically active protein. The milk containing the biologically active protein or the biologically active protein itself can be used in the making of diary products. | ||||||
| 125 | Milk products having high concentrations of omega-3 highly unsaturated fatty acids | US918325 | 1997-08-26 | US5985348A | 1999-11-16 | William R. Barclay |
| A process for the heterotrophic or predominantly heterotrophic production of whole-celled or extracted microbial products with a high concentration of omega-3 highly unsaturated fatty acids, producible in an aerobic culture under controlled conditions using biologically pure cultures of heterotrophic single-celled fungi microorganisms of the order Thraustochytriales. The harvested whole-cell microbial product can be added to processed foods as a nutritional supplement, or to fish and animal feeds to enhance the omega-3 highly unsaturated fatty acid content of products produced from these animals. The lipids containing these fatty acids can also be extracted and used in nutritional, pharmaceutical and industrial applications. | ||||||
| 126 | Refrigeration-shelf-stable ready-to-drink complete nutritional compositions and products | US975692 | 1997-11-21 | US5985339A | 1999-11-16 | A. Reza Kamarei |
| Refrigeration-shelf-stable ready-to-drink complete nutritional products such as nutritional supplements, foods for special dietary use, and medical foods can be prepared through an ultra-pasteurization and/or pasteurization process. By varying the choice and quantity of nutritional and functional ingredients, and by varying processing conditions, various such products can be obtained that specifically target the nutritional and health needs of different health conditions and diseases in both healthy individuals and patient populations. Daily values for calories, carbohydrates, fat, protein, minerals and vitamins are calculated to provide a complete nutritional product which when consumed within the refrigeration shelf-life will have substantially maintained its completeness. | ||||||
| 127 | Transgenic non-human mammal milk comprising 2'-fucosyl-lactose | US208889 | 1994-03-09 | US5750176A | 1998-05-12 | Pedro Antonio Prieto; David Fletcher Smith; Richard Dale Cummings; John Joseph Kopchick; Pradip Mukerji; Kelley Wilson Moremen; James Michael Pierce |
| The invention relates to the milk of a transgenic non-human mammal. The milk is characterized in that it contains heterologous components produced as the secondary gene products of a heterologous gene contained in the genome of the transgenic non-human mammal. The heterologous gene encodes a heterologous catalytic entity such as a human enzyme selected from the group consisting of glycosyltransferases, phosphorylases, hydroxylases, peptidases and sulfotransferases. Especially useful in the practice of the invention are human glycosyltransferases. The desired heterologous components include oligosaccahrides, glycoconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding .alpha.-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter. The oligosaccahrides and glycoconjugates may be isolated from the milk of the transgenic mammals and used in the preparation of pharmaceuticals, diagnostic kits, nutritional products and the like. The whole transgenic milk may also be used to formulate nutritional products that provide special advantages. The transgenic milk may also be used in the production of specialized enteral nutritional products. | ||||||
| 128 | Transgenic bovine | US461333 | 1995-06-05 | US5741957A | 1998-04-21 | Herman A. Deboer; Rein Strijker; Herbert L. Heyneker; Gerard Platenburg; Sang He Lee; Frank Pieper; Paul J. A. Krimpenfort |
| A transgenic bovine is disclosed whose somatic and germ cells contain a transgene, wherein the transgene comprising a mammary gland specific promoter, a mammary gland specific enhancer, a DNA sequence encoding a signal sequence functional in bovine mammary gland secretory cells and a DNA sequence encoding a heterologous polypeptide of interest wherein the transgenic bovine expresses the transgene such that the polypeptide of interest is detectable in milk produced by the transgenic bovine. | ||||||
| 129 | Method for raising animals having high concentrations of omega-3 highly unsaturated fatty acids | US483477 | 1995-06-07 | US5698244A | 1997-12-16 | William R. Barclay |
| A process for the heterotrophic or predominantly heterotrophic production of whole-celled or extracted microbial products with a high concentration of omega-3 highly unsaturated fatty acids, producible in an aerobic culture under controlled conditions using biologically pure cultures of heterotrophic single-celled fungi microorganisms of the order Thraustochytriales. The harvested whole-cell microbial product can be added to processed foods as a nutritional supplement, or to fish and animal feeds to enhance the omega-3 highly unsaturated fatty acid content of products produced from these animals. The lipids containing these fatty acids can also be extracted and used in nutritional, pharmaceutical and industrial applications. | ||||||
| 130 | Method of producing a transgenic bovine or transgenic bovine embryo | US154019 | 1993-11-16 | US5633076A | 1997-05-27 | Herman A. DeBoer; Rein Strijker; Herbert L. Heyneker; Gerard Platenburg; Sang H. Lee; Frank Pieper; Paul J. A. Krimpenfort |
| A method is disclosed for the production of a transgenic bovine or a transgenic bovine embryo comprising obtaining an ovum from bovine ovaries, maturing the ovum in vitro, fertilizing the mature ovum or ova in vitro to form a zygote, introducing a transgene into the zygote in vitro and maturing the zygote to a preimplantation stage embryo in vitro. To produce the transgenic bovine, the embryo is transplanted into a recipient female bovine, wherein the female bovine gestates the embryo to produce a transgenic bovine. | ||||||
| 131 | Manufacture of anti-regurgitant milk for infants | US166447 | 1993-12-13 | US5429837A | 1995-07-04 | Christine Balabaud; Alain Loones |
| A process for the manufacture of anti-regurgitation infant milk is disclo wherein the milk is preheated, homogenized, and treated at ultra high temperatures and wherein a thickening agent, such as carob, guar, carrageenans, or pectins, is added prior to the homogenization step in an amount of between 0.3% and 1.0% by weight of the milk. The milk is then packaged under aseptic conditions in sterile packages. | ||||||
| 132 | Aseptic processing of infant formula | US075191 | 1993-06-10 | US5378488A | 1995-01-03 | Steven R. Dimler; David V. Diodato; Terrence B. Mazer; Daniel L. McKamy; James M. Simpson |
| A process for aseptically processing a milk based infant formula includes the steps of adding citrate ions to the formula at a concentration of at least 128 ppm and adjusting the pH to be at least 6.8 before subjecting the formula to a temperature of at least 132.degree. C. | ||||||
| 133 | Anti-inflammatory factor, method of isolation, and use | US580382 | 1990-09-11 | US5242691A | 1993-09-07 | Lee R. Beck |
| The invention relates to a substantially pure anti-inflammatory factor isolated from milk collected from a milk producing animal, to the purification, identification, and characterization of said factor, and to a method for treating inflammation in an animal which comprises administering to the animal an anti-inflammatorally effective amount of the anti-inflammatory factor. In a preferred embodiment, the factor is isolated from milk is produced by a milk producing animal maintained in a hyperimmunized state. | ||||||
| 134 | Recombinant bile salt activated lipases | US537426 | 1990-06-12 | US5200183A | 1993-04-06 | Jordan J. N. Tang; Chi-Sun Wang |
| The complete structure of human milk BAL cDNA is disclosed. The nucleotide sequences of the cDNA inserts of two clones overlap and together contain 2951 base pairs of BAL cDNA which codes for an open reading frame of 742 amino acid residues between initiation and termination codons. There is a putative signal sequence of 20 residues which is followed by a 61-amino-terminal sequence of BAL. The cDNA sequence also contains a 678-base 5'-untranslated sequence, a 97-base 3'-untranslated region, and a 14-base poly(A) tail. The deduced BAL protein structure contains in the carboxyl-terminal region fourteen repeating unis of 11 amino acids each. The repeating units have the basic structure of Pro-Val-Pro-Pro-Thr-Gly-Asp-Ser-Gly-Ala-Pro-, with only minor substitutions. The cDNA is useful for expression of protein, study of structure, function and the effect of modification or deletion or addition of amino acids, including entire repeating units, and as probes for studies involving BAL or related lipases, including rat pancreatic lysophospholipase, cholinesterase, and acetylcholinesterase. | ||||||
| 135 | Antihypertensive hyperimmune milk, production, composition, and use | US431773 | 1989-11-06 | US5194255A | 1993-03-16 | Lee R. Beck; Ralph J. Stolle |
| The invention relates to a method for inducing the production of a milk anti-hypertensive factor in an animal, to a method for the isolation of said factor from the milk of said animal in a substantially pure form, and to the use of said factor to treat hypertension in humans and other animals, and to compositions containing the anti-hypertensive factor. | ||||||
| 136 | Use of honey as vaccine | US431639 | 1989-11-06 | US5130128A | 1992-07-14 | Ralph J. Stolle |
| Anti-honey food products are disclosed, such food products being obtained from animals hyperimmunized against at least one antigen found in honey, and preferably whole unfractionated honey. A vaccine producing said anti-honey food product is disclosed, said vaccine comprising at least one honey antigen and preferably whole unfractionated honey. Further, a dietary supplement for humans and especially infants which protects against harmful allergens and microorganisms found in honey is disclosed, said supplement comprising the anti-honey eggs or milk or fractions thereof. | ||||||
| 137 | Process for preparing phosphorus-reduced cow milk | US337611 | 1989-04-05 | US4968513A | 1990-11-06 | Shiro Watanabe; Hiroshi Nakashima |
| The phosphorus-reduced cow milk of the invention contains a reduced proportion of phosphorus of 1.0 g to 2.0 g per 100 g of protein in the cow milk, the weight ratio of phosphorus to calcium being 1:2, nearly the same as that of human milk. The ratio is most adequate for calcium absorption and is suitable as food for kidney-disease patients with reduced calcium-absorbing function, persons of old age and hyperphosphatemia patients. Moreover, the phosphorus-reduced cow milk of the invention in which only phosphorus component is selectively removed and none of other component is lost maintains the value of cow milk as perfect food. | ||||||
| 138 | Compositions and method for decomposing adipose tissue | US914681 | 1986-10-02 | US4859468A | 1989-08-22 | Michinori Kubo; Reiko Matsuda |
| Solvent extracts of Piper angustifolium and/or Boldea fragrans have excellent adipose tissue decomposing activity.These extracts, if administered in appropriate drug forms, provide effective remedy of corpulent constitution and if these extracts are added to any food or beverage, their ingestion enables control of overweight. | ||||||
| 139 | Infant foods | US48547 | 1987-05-11 | US4753926A | 1988-06-28 | Alan Lucas; Richard I. Barr |
| Infant foods suitable for use in the feeding of low birthweight infants, more especially preterm infants, are disclosed. The foods contain a relatively high level of vitamin B.sub.2 and may be prepared so as to have an opacity greater than that of human breast milk leading to less susceptibility of the vitamin B.sub.2 to breakdown by UV-light when used for the feeding of low birthweight infants who are receiving phototherapy. Preferred infant foods according to the invention also have high contents of vitamin B.sub.6, vitamin C, vitamin D, vitamin E, folic acid, copper and zinc while containing no added iron. Another aspect of the invention is the inclusion of taurine and carnitine. One unexpected property of the infant foods according to the invention with high vitamin content is that their use has been found to reduce the incidence of hyperbilirubinaemia in low birthweight infants. | ||||||
| 140 | Nutritional supplement preparation intended for pregnant and breast-feeding women based on milk constituents as well as a process for preparing it | US795973 | 1985-11-07 | US4710387A | 1987-12-01 | Dirk J. D. Uiterwaal; Aart Hersevoort |
| Nutritional supplement preparation for pregnant and breast-feeding women based on milk constituents for pregnant and breast-feeding women containing 10-20% by weight of protein, 16-28% by weight of fat, 43-65% by weight of carbohydrates, at most 3.5% by weight of moisture and minerals, trace elements and vitamins such as calcium, phosphorus, magnesium, copper, zinc, iodine, iron, vitamin A, vitamin B1, vitamin B6, vitamin C, vitamin D3, vitamin E, niacin and folic acid, and, optionally flavoring and/or colorant as well as a process for preparing said preparation. | ||||||
QQ群二维码
意见反馈
意见反馈